Qualifying Therapeutic Discovery Project Grants for the State of Tennessee
The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.
The project descriptions below were extracted from the applicant certification forms as submitted.
| Applicant Name | Project Name | Grants Awarded for 2009 | Grants Awarded for 2010 |
|---|---|---|---|
| Advanced Breath Diagnostics, LLC | 13C-Spirulina Gastric Emptying Breath Test ("GEBT") | $ 244,479.24 | |
| Asklepion Pharmaceuticals LLC | Citrulline | $ 244,479.25 | |
| Asklepion Pharmaceuticals LLC | Cholic Acid | $ 72,395.14 | $ 172,084.11 |
| BioMimetic Therapeutics Inc | Orthopedic Program | $ 244,479.25 | |
| BioMimetic Therapeutics Inc | Sports Medicine Research and Development Program | $ 244,479.25 | |
| Cumberland Pharmaceuticals Inc | Cumberland TPr Antagonist | $ 13,483.50 | $ 230,995.75 |
| Cumberland Pharmaceuticals Inc. | Cumberland Caldolor Pediatrics | $ 57,556.50 | $ 186,922.75 |
| Cumberland Pharmaceuticals Inc. | Cumberland Acetadote ALF | $ 51,000.00 | $ 77,229.50 |
| Cumberland Pharmaceuticals, Inc | Cumberland Acetodate EF | $ 67,886.00 | $ 176,593.25 |
| ED Laboratories, Inc | EDL 2000 | $ 104,060.50 | $ 140,418.75 |
| EDP Biotech Corporation | ColoMarker | $ 244,479.25 | |
| ExtraOrtho Inc | Biopolymer Sponge | $ 244,479.25 | |
| Glenveigh Pharmaceuticals LLC | Belfort-Dildy Obstetric Tamponade System (BD OTS) | $ 244,479.25 | |
| GLENVEIGH PHARMACEUTICALS, LLC | DEVICE FOR MEASURING CERVICAL DILATION DURING ACTIVE LABOR | $ 48,589.50 | $ 32,607.50 |
| Glenveigh Pharmaceuticals, LLC | Development of Therapeutic and Diagnostic for Preeclampsia (Project DIF) | $ 109,469.00 | $ 46,957.50 |
| GTx | ALK Inhibition Therapy | $ 244,479.24 | |
| GTx, Inc | Toremifene 20mg | $ 244,479.24 | |
| GTx, Inc. | Ostarine | $ 244,479.24 | |
| GTx, Inc. | GTx-758 | $ 244,479.24 | |
| GTx, Inc. | Toremifene 80mg | $ 244,479.24 | |
| Hematotypes, Inc. | Rapid multiparameter immunophenotyping of target cell populations | $ 5,182.00 | $ 3,956.00 |
| Insight Genetics, Inc | Novel Molecular Diagnostic Tests for Cancers Driven by Anaplastic Lymphoma Kinase (ALK) | $ 244,479.25 | |
| InVivoLink, LLC | InVivoLink Implant Registry | $ 80,621.00 | $ 163,858.25 |
| Molecular Design International, Inc. | Compound 49b prevents retinopathy | $ 225,000.00 | $ 19,479.24 |
| NellOne Therapeutics Inc | Development of novel cardiac and skeletal muscle regenerating therapy | $ 113,397.50 | $ 131,081.74 |
| Pathfinder Therapeutics, Inc | Image-Guided Cancer Therapeutic Delivery System | $ 244,479.25 | |
| Provectus Pharmaceuticals, Inc. | Pharmaceutical agent PV-10 | $ 244,479.24 | |
| RxBio, Inc. | Rx100 | $ 182,397.50 | $ 62,081.75 |
| Surgivision, Inc | ClearPoint | $ 244,479.25 | |
| SURGIVISION, INC. | SafeLead | $ 244,479.25 |
References/Related Topics
Page Last Reviewed or Updated: 2012-10-12
